Metastatic gastrointestinal stromal tumors in the era of imatinib: improved survival and elimination of socioeconomic survival disparities

Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology
Avo ArtinyanJoshua D I Ellenhorn

Abstract

Imatinib was approved in 2002 for unresectable and metastatic gastrointestinal stromal tumors. Our objective was to determine if the introduction of imatinib coincided with improved survival from metastatic gastrointestinal stromal tumor in the U.S. population and in specific socioeconomic groups. Query of the Surveillance, Epidemiology, and End Results registry identified 552 patients with metastatic gastrointestinal stromal tumor between 1995 and 2004. Year of diagnosis was categorized into two periods, 1995 to 2000 and 2001 to 2004, to account for the effect of imatinib. Kaplan-Meier and multivariate Cox regression analyses were used to examine differences in survival between periods and among socioeconomic groups. Median survival increased from 12 to 33 months from 1995 to 2000 to 2001 to 2004 (P < 0.001); survival at 47 months increased from 21% to 41%, respectively (P < 0.001). Median survival times for White, Black, Hispanic, and Asian or Pacific Islander, and for low-, middle-, and high-income groups increased significantly in the era of imatinib (all P < 0.05). On multivariate analysis, Black race [hazard ratio, 1.96; 95% confidence interval (95% CI), 1.15-3.32; P = 0.013], Hispanic race (hazard ratio, 2.11; 95% CI, 1....Continue Reading

References

Jun 26, 1998·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·B D HotchkissR Lisitano
Oct 26, 2000·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·M MiettinenM Sarlomo-Rikala
Feb 28, 2002·American Journal of Clinical Pathology·Jason L Hornick, Christopher D M Fletcher
Apr 3, 2002·Archives of Internal Medicine·Marie A Chisholm, Joseph T DiPiro
Aug 16, 2002·The New England Journal of Medicine·George D DemetriHeikki Joensuu
Apr 4, 2003·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Yoshiya FujimotoTadakazu Shimoda
Aug 15, 2003·International Journal of Cancer. Journal International Du Cancer·Eva WardelmannSabine Merkelbach-Bruse
Dec 4, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael C HeinrichJonathan A Fletcher
Jan 19, 2005·The American Journal of Gastroenterology·Thomas TranHashem B El-Serag
May 19, 2005·International Journal of Cancer. Journal International Du Cancer·Geir TryggvasonJón G Jónasson
Jun 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christopher L CorlessMichael C Heinrich
Sep 8, 2006·Annals of Surgical Oncology·S BonvalotA Le Cesne
Oct 5, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H Joensuu
Jan 9, 2007·Annals of Surgical Oncology·Eduardo A PerezLeonidas G Koniaris
May 22, 2007·Lancet·Brian P RubinChristopher L Corless
Oct 9, 2007·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Salah-Eddin Al-BatranElke Jäger
Jan 19, 2008·Journal of Cancer Research and Clinical Oncology·M A PantaleoG Biasco
Feb 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles D BlankeHeikki Joensuu

❮ Previous
Next ❯

Citations

May 4, 2010·Clinics in Colon and Rectal Surgery·Elizabeth A Peralta
Sep 4, 2012·Clinics in Colon and Rectal Surgery·Dimitra G Theodoropoulos
Sep 5, 2015·Journal of Gastrointestinal Cancer·Jacopo Giuliani, Andrea Bonetti
Feb 2, 2012·International Journal of Breast Cancer·Silvia C FormentiSusan M Love
Apr 22, 2008·Expert Opinion on Pharmacotherapy·Philippe A CassierJean-Yves Blay
Aug 5, 2009·Journal of the American College of Surgeons·Michael C CheungLeonidas G Koniaris
Aug 30, 2017·British Journal of Cancer·Heikki JoensuuAxel Le Cesne
Aug 23, 2019·World Journal of Gastroenterology : WJG·Johanna WaidhauserBruno Märkl
Jul 21, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Belinda ThewesJudith B Prins
Dec 6, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ipek Özer-StillmanKatherine E Tranbarger-Freier
Mar 11, 2009·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Ying ZhugeLeonidas G Koniaris
May 14, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J-Y Blay

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of the American College of Surgeons
Juan C GutierrezLeonidas G Koniaris
Annals of Oncology : Official Journal of the European Society for Medical Oncology
J Y BlayA Le Cesne
© 2022 Meta ULC. All rights reserved